OOIR: Observatory of International Research

Papers

(The median citation count of Blood Reviews is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	130
Radiation and leukaemia: Which leukaemias and what doses?	126
Editorial Board	123
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	83
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	59
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	59
Clinical burden of hemophilia in older adults: Beyond bleeding risk	54
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	51
Artificial intelligence in sickle disease	49
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	45
Advances in the critical care management for patients with hematological malignancies	43
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	42
Thalassaemia in China	41
Not all LGL leukemias are created equal	40
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	39
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	39
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	38
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	38
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	35
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	35
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	34
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	34
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	33
Chasing leukemia differentiation through induction therapy, relapse and transplantation	33

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	31
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	31
Preservation of fertility in female patients with hematologic diseases	30
Immune thrombocytopenia: A review of upfront treatment strategies	29
Endothelial cells: major players in acute myeloid leukaemia	29
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	28
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	28
Current challenges in conditioning regimens for MDS transplantation	28
CHIPing away the progression potential of CHIP: A new reality in the making	28
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	27
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	27
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	26
Richter's transformation: Transforming the clinical landscape	26
Down syndrome and leukemia: An insight into the disease biology and current treatment options	25
Optimizing high dose melphalan	25
Current state and next-generation CAR-T cells in multiple myeloma	24
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	24
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	23
The mythological chimera and new era of relapse prediction post-transplant	22
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	22
Complementary and alternative medicine for children with sickle cell disease: A systematic review	21
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	21
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	21
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	20
Αlpha-thalassemia: A practical overview	20
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	20
Beyond the blood: A practical guide to thalassemia care in the emergency department	20
AML and the art of remission maintenance	19
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	19
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	19
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	19
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	18
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	18
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	18
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	18
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	17
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	17
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	16
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	16
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	16
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	16
Innovations in red blood cell preservation	16
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	15
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	15
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	15
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies	15
The use of bone-modifying agents in multiple myeloma	15

Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021	15
The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators	14
Antibiotics to modify sickle cell disease vaso-occlusive crisis?	14
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	14
Combining PTCy and ATG for GvHD prophylaxis in non-malignant diseases	14
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	14
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme	13
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B	13
Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets	13
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia	13
De-novo immune-mediated thrombotic thrombocytopenic purpura following surgical and non-surgical procedures: A systematic review	13
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2	13
Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol	12
Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies	12
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review	12
Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research	12
The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia?	12
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	12
Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research	12
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS	12
Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China	12
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	11
Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody	11
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	11
Chronic myeloid leukaemia: Biology and therapy	11
Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: The good, the bad, the ugly	11
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML	10
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies	10
Editorial Board	10
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond	10
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	10
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	10
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution	10
Evans syndrome revisited	10
Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies	10
Follicular lymphoma: The long and winding road leading to your cure?	10
Unmet needs in hemophilic arthropathy	10
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management	10
Disparity in hematological malignancies: From patients to health care professionals	10
Autologous stem cell transplantation in AL amyloidosis: Muddy waters	10
The development of post-transplant cyclophosphamide: Half a century of translational team science	10
Editorial Board	9
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment	9
Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era	9
Continuing progress in radioimmunotherapy for hematologic malignancies	9
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH	9
BCL-2 inhibition in haematological malignancies: Clinical application and complications	9
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	9
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches	9
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?	9
Decoding DNA methylation in epigenetics of multiple myeloma	9
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	8
A review of FLT3 inhibitors in acute myeloid leukemia	8
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	8
Dismantling relapsed/refractory mantle cell lymphoma	8
Could (should) we abandon total body irradiation for conditioning in children with leukemia	8
From MGUS to multiple myeloma: Unraveling the unknown of precursor states	8
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	8
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review	8
Corrigendum to “Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?”[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]	8
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances	8
Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma	7
CLL update 2022: A continuing evolution in care	7
Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis	7
Editorial Board	7
Acupuncture in hematologic malignancies and hematopoietic cell transplantation	7
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies	7
Prognostic performance of machine learning in predicting haematological cancer outcomes: systematic review and meta-analysis	7
Navigating the perils and pitfalls throughout the consent process in hematopoietic cell transplantation	7
Knowing the unknowns in high risk multiple myeloma	7
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	7